UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/533,501	05/02/2005	Jeffrey Michael Axten	P51380	4465
	7590 01/18/200 BEECHAM CORPOR		EXAM	INER
CORPORATE INTELLECTUAL PROPERTY-US, UW2220 P. O. BOX 1539			HABTE, KAHSAY	
	KING OF PRUSSIA, PA 19406-0939		ART UNIT	PAPER NUMBER
			1624	
			NOTIFICATION DATE	DELIVERY MODE
			01/18/2008	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

US_cipkop@gsk.com

	Application No.	Applicant(s)			
Office Action Occurrence	10/533,501	AXTEN ET AL.			
Office Action Summary	Examiner	Art Unit			
	Kahsay T. Habte	1624			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence ad	ldress		
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	J. nely filed the mailing date of this c D (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on					
	- action is non-final.				
3) Since this application is in condition for allowan					
closed in accordance with the practice under E					
Disposition of Claims					
 4) Claim(s) 1-11 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-11 are subject to restriction and/or expressions. 					
Application Papers					
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the confidence of the	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CI	, ,		
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priori application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No ed in this National	Stage		
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	nte			

DETAILED ACTION

1. Claims 1-11 are pending in this application.

Election/Restrictions

2. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-11 (in part), drawn to R^2 = benzothiazine (see formula I-4 at page 14).

Group II, claim(s) 1-11 (in part), drawn to R^2 = benzoxazine (see formula III-2 at page 16).

Group III, claim(s) 1-11 (in part), drawn to R^2 = pyrido[3,2-b]thiazine (see formula V-4 at page 18).

Group IV, claim(s) 1-11 (in part), drawn to R^2 = pyrido[3,2-b]oxazine (see Example 3 at page 38).

Group V, claim(s) 1-11 (in part), drawn to R^2 = others.

The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature of Group I is benzothazine ring (benzo ring fused to 1,4-thiazine ring) and is different from the special technical feature of Group II-V. The special technical feature

of Group II is benzoxazine ring (a benzo ring fused to 1,4-oxazine ring) and is different from the special technical feature of Groups I and III-V. The special technical feature of Group III is a pyrido[3,2-b]thiazine ring (pyrido ring fused to 1,4-thiazine ring) and is different from the special technical feature of Groups I-II and IV-V. The special technical feature of Group IV is a pyrido[3,2-b]oxazine ring (pyrido ring fused to 1,4-oxazine ring) and is different from the special technical feature of Groups I-III and V. The special technical feature of Group V is others e.g. benzodioxine ring, dioxino[2,3-b]pyridine ring, different bicyclic carbocyclic ring, etc. and is different from the special technical feature of Groups I-IV.

If applicants elect Group V, an election of a single disclosed species is required.

A telephone call was made to Ms. Loretta Sauermeich on 1/15/2008 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Application/Control Number: 10/533,501 Page 4

Art Unit: 1624

Conclusion

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kahsay Habte whose telephone number is (571) 272-0667. The examiner can normally be reached on M-F (9.00AM- 5:30PM).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached at (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Kahsay T. Habte/ Primary Examiner, Art Unit 1624

January 16, 2008

Application/Control Number: 10/533,501

Page 5

Art Unit: 1624